Data presented at obesity week demonstrate that gelesis investigational clinical-stage oral superabsorbent hydrogel gel-b preferentially enhances the growth of akkermansia muciniphila in preclinical models compared to prebiotics

Boston--(business wire)--gelesis holdings inc. (nyse: gls) (“gelesis” or the “company”) the maker of plenity for weight management, today released new data at obesity week in san diego.
GLS Ratings Summary
GLS Quant Ranking